<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141310</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Recommendations on use of direct oral anticoagulants in the perioperative period</dc:title>
<dc:description xml:lang="en">Because of the characteristics of direct oral anticoagulants (DOA), the lack of an antidote to completely reverse their anticoagulant effects, the absence of standardization in monitoring of their effects, and limited experience of their use, specific recommendations for their management in the perioperative period or in emergencies are required. In elective surgery, in patients with normal renal function and low hemorrhagic/ thrombotic risk, DOA should be withdrawn 2 days before the intervention; when the hemorrhagic/ thrombotic risk is higher, bridge therapy with a low molecular weight hepatin beginning 5 days before the intervention is proposed as an alternative. In emergency surgery, systematic administration of hemostatic drugs as prophylaxis is not recommended. In DOA-related acute hemorrhage, administration of prothrombin complex concentrate, fresh plasma or factor VIIa should be evaluated, and general measures to control bleeding should be implemented (AU)</dc:description>
<dc:creator>Torres, Luis M</dc:creator>
<dc:creator>Gómez-Luque, Aurelio</dc:creator>
<dc:creator>Llau, Juan V</dc:creator>
<dc:creator>Hidalgo, Francisco</dc:creator>
<dc:creator>Ferrandis, Raquel</dc:creator>
<dc:creator>Gomar, Carmen</dc:creator>
<dc:creator>Castillo, Jorge</dc:creator>
<dc:creator>Andrés, José de</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las características de los anticoagulantes orales de acción directa (ACOD), la ausencia de antídoto para revertir completamente sus efectos anticoagulantes, la falta de sistematización en la monitorización de sus efectos y la experiencia limitada de su empleo, hacen necesarias unas recomendaciones específicas para su uso en el periodo perioperatorio o ante situaciones de urgencia. En cirugía programada, en pacientes con función renal normal y riesgos hemorrágico/trombótico bajos, se recomienda suspender el ACOD 2 días antes de la cirugía; en situaciones de mayor riesgo hemorrágico/trombótico se propone como alternativa una terapia puente con una heparina de bajo peso molecular desde 5 días antes de la cirugía. Ante cirugía urgente no se recomienda la administración sistemática de hemostáticos de forma profiláctica. En caso de hemorragia aguda relacionada con la toma de un ACOD, se debe valorar la administración de concentrados de complejo protrombínico, plasma fresco o factor VIIa, implementando las medidas generales de control de la hemorragia (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);139(supl.2): 46-50, oct. 2012. tab, ilus</dc:source>
<dc:identifier>ibc-141310</dc:identifier>
<dc:title xml:lang="es">Recomendaciones de uso de los anticoagulantes orales directos en el período perioperatorio</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d932^s22020</dc:subject>
<dc:subject>^d33563^s22045</dc:subject>
<dc:subject>^d1585^s22073</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d32645^s22036</dc:subject>
<dc:subject>^d1585^s22020</dc:subject>
<dc:subject>^d14260^s22020</dc:subject>
<dc:subject>^d14260^s22073</dc:subject>
<dc:subject>^d32645^s22054</dc:subject>
<dc:subject>^d52618^s22054</dc:subject>
<dc:subject>^d12157^s22073</dc:subject>
<dc:subject>^d28178^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28875^s22054</dc:subject>
<dc:subject>^d30298^s22003</dc:subject>
<dc:subject>^d28178^s22073</dc:subject>
<dc:subject>^d12165^s22073</dc:subject>
<dc:subject>^d12157^s22020</dc:subject>
<dc:subject>^d30298^s22073</dc:subject>
<dc:subject>^d286</dc:subject>
<dc:subject>^d30298^s22020</dc:subject>
<dc:subject>^d12165^s22020</dc:subject>
<dc:subject>^d36291</dc:subject>
<dc:type>article</dc:type>
<dc:date>201210</dc:date>
</metadata>
</record>
</ibecs-document>
